GRM5 and Parkinson disease: Moreover, in the recent study of this group, they found that mGlu5 agonists inhibit α-synuclein-mediated neuroinflammation by regulating the binding of mGlu5 to α-synuclein (Zhang Y.N. et al., 2021), further indicating the significant role of mGlu5 in PD.